20
10
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T12731 |
RIPK1-IN-7
|
RIP kinase | Apoptosis; NF-κB |
RIPK1-IN-7 是一种选择性有效的 RIPK1 抑制剂,Kd 值为 4 nM,IC50值为 11 nM。在实验性 B16 黑色素瘤肺转移模型中表现出优异的抗转移活性。 | |||
T2358 |
ENMD-2076
|
Apoptosis; VEGFR; FGFR; FLT; c-RET; PDGFR; Src; Aurora Kinase | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors |
ENMD2076是一种多靶点激酶抑制剂,抑制Aurora A、Flt3、KDR/VEGFR2、Flt4/VEGFR3、FGFR1、FGFR2、Src、PDGFRα的IC50值分别为1.86、14、58.2、15.9、92.7、70.8、20.2 and 56.4 nM。 | |||
TQ0166 |
Tesevatinib
KD-019,XL-647,EXEL-7647 |
EGFR; VEGFR; FLT; Ephrin Receptor | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Tesevatinib (XL-647) 是一种口服的多靶点酪氨酸激酶抑制剂,对 EGFR、ErbB2、KDR、Flt4和 EphB4的 IC50值分别为 0.3、16、1.5、8.7和 1.4 nM。 | |||
T5164 |
Cabozantinib hydrochloride
XL184,Cabozantinib hydrochloride (849217-68-1(free base)),BMS-907351,盐酸卡博替尼 |
VEGFR; FLT; c-Met/HGFR; TAM Receptor; c-Kit; ROR | Angiogenesis; Metabolism; Tyrosine Kinase/Adaptors |
Cabozantinib hydrochloride (XL184) 是一种有效的泛酪氨酸激酶抑制剂,可抑制 VEGFR2、c-Met、Kit、Axl 和 Flt4(IC50:0.035、1.3、4.6、7 和 6 nM)。 | |||
T2617 |
SNS-314 Mesylate
SNS-314 |
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
SNS-314 Mesylate (SNS-314) 是一种有效且特异性的极光激酶抑制剂,对极光激酶 A、B、C 的 IC50值分别为 9,31 和 3 nM。 | |||
T9556 |
TNIK-IN-3
|
Wnt/beta-catenin | Cytoskeletal Signaling; Stem Cells |
TNIK-IN-3 is a highly potent and orally active inhibitor of Traf2- and Nck-interacting protein kinase (TNIK). It exhibits a strong selectivity for TNIK with an IC50 value of 0.026 μM. Additionally, TNIK-IN-3 demonstrates inhibitory activity against Flt4 (IC50 = 0.030 μM), Flt1 (IC50 = 0.191 μM), and DRAK1 (IC50 = 0.411 μM). This compound holds potential for carrying out research on colorectal cancer (CRC) [1]. | |||
T2638 |
Gandotinib
LY2784544 |
VEGFR; FGFR; FLT; JAK | Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
Gandotinib (LY2784544) 是一种JAK2抑制剂,IC50为 3 nM。它也抑制FLT3、FLT4、FGFR2、TYK2 和 TRKB,IC50分别为 4、25、32、44 和 95 nM。 | |||
T1656 |
Vandetanib
ZD6474,凡德他尼 |
Apoptosis; EGFR; VEGFR; Autophagy | Angiogenesis; Apoptosis; Autophagy; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Vandetanib (ZD6474) 是一种具有口服活性的VEGFR2/KDR 酪氨酸激酶抑制剂,IC50值为40 nM。它也抑制VEGFR3/FLT4和EGFR/HER1,IC50值分别为110和500 nM。 | |||
T2500 |
Cediranib
AZD2171,NSC-732208,西地尼布 |
VEGFR; FLT; PDGFR; c-Kit; Autophagy | Angiogenesis; Autophagy; Tyrosine Kinase/Adaptors |
Cediranib (AZD2171) 是一种可口服的高选择性VEGFR2抑制剂,对Flt1、KDR、Flt4、PDGFRα、PDGFRβ和c-Kit 的IC50值分别为小于1、小于3、5、5、36和 2nM。 | |||
T21641 |
Vandetanib hydrochloride
|
||
Vandetanib hydrochloride (D6474 hydrochloride) 是一种有效的,口服的VEGFR2/KDR 酪氨酸激酶抑制剂 (IC50=40 nM)。Vandetanib hydrochloride 对于VEGFR3/FLT4(IC50=110 nM) 和EGFR/HER1(IC50=500 nM)也有抑制作用。 | |||
T35570 |
Chiauranib
CS2164,西奥罗尼 |
c-Fms; VEGFR; FLT; PDGFR; c-Kit; Aurora Kinase | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors |
Chiauranib 是一种针对肿瘤血管生成的多靶点抑制剂,具有强大的抗癌作用。 Chiauranib 有效抑制血管生成相关激酶(VEGFR1、VEGFR2、VEGFR3、PDGFRα 和 c-Kit)、有丝分裂相关激酶 Aurora B 和慢性炎症相关激酶 CSF1R,IC50 值范围为 1-9 nM。 | |||
T64176 |
Vandetanib trifluoroacetate
|
||
Vandetanib trifluoroacetate (D6474 trifluoroacetate) 是一种口服具有活力的、有效的 VEGFR2/KDR 酪氨酸激酶抑制剂,其 IC50 值为 40 nM。Vandetanib trifluoroacetate 对 VEGFR3/FLT4 和 EGFR/HER1 也表现出抑制作用,他们的 IC50 值分别为 110 nM、500 nM。 | |||
T79368 | Antiproliferative agent-34 | EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Antiproliferative agent-34 (Compound A14) 是一种多激酶抑制剂,能有效抑制包括EGFRL858R/T790M在内的特定EGFR基因变异形式,IC50为177 nM,对EGFRWT则为1567 nM。它还能抑制JAK2、ROS1、FLT3、FLT4和PDGFRα的活性,其IC50分别为30.93、106.90、108.00、226.60和42.53 nM。在正常氧气环境中,Antiproliferative agent-34对H1975和HCC827细胞株的抑制IC50值低于40 nM,而在低氧环境下,其抑制效能增强4至6倍,IC50值降至低于10 nM。 | |||
T4349 |
Sitravatinib
MG516,MGCD516 |
Discoidin Domain Receptor (DDR); VEGFR; FLT; Trk receptor; TAM Receptor; c-Kit; Ephrin Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
Sitravatinib (MGCD516) 是一种有口服活性的受体酪氨酸激酶抑制剂。它单独使用即具有有效的抗肿瘤功效,且通过促进抗肿瘤免疫微环境增强了 PD-1 阻断的活性。 | |||
T0520 |
Lenvatinib
仑伐替尼,E7080 |
VEGFR; FGFR; c-RET; PDGFR; c-Kit | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Lenvatinib (E7080) 是一种多靶点受体酪氨酸激酶抑制剂,抑制 VEGFR1-3、FGFR1-4、KIT、PDGFR 和 RET 等,具有口服活性。Lenvatinib 对 VEGFR2 和 VEGFR3 的抑制活性最强 (IC50=4/5.2 nM)。Lenvatinib 具有强效抗肿瘤活性。 | |||
T6720 |
Vatalanib dihydrochloride
CGP-797870 dihydrochloride,ZK-222584 dihydrochloride,Vatalanib 2HCl,PTK787 dihydrochloride,Vatalanib (PTK787) 2HCl,CGP-79787 dihydrochloride,瓦他拉尼 |
Apoptosis; VEGFR; PDGFR | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Vatalanib dihydrochloride (PTK787 dihydrochloride) 是一种VEGFR2/KDR 的抑制剂,其IC50值为37nM。 | |||
T3113 |
Foretinib
GSK089,EXEL-2880,GSK1363089,XL880 |
VEGFR; Tie-2; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Foretinib (GSK1363089) 是多靶点酪氨酸激酶抑制剂,能够抑制 Met (IC50:0.4 nM) 和 KDR (IC50:0.9 nM)。 | |||
T13564 |
AZ7550
|
MLK; FAK; EGFR; FLT; Tyrosine Kinases; PYK2; MNK; IGF-1R; ACK; BTK; ALK; Drug Metabolite | Angiogenesis; Cytoskeletal Signaling; JAK/STAT signaling; MAPK; Metabolism; Tyrosine Kinase/Adaptors |
AZ7550 是 AZD9291 的活性代谢物,可抑制 IGF1R 活性,IC50为 1.6 μM。 | |||
T13564L |
AZ7550 hydrochloride
AZ7550 hydrochloride (1421373-99-0 free base) |
EGFR; IGF-1R | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
AZ7550 hydrochloride (AZ7550 hydrochloride ) 是 AZD9291 的活性代谢物,可抑制 IGF1R 活性,IC50为 1.6 μM。 | |||
T2500L |
Cediranib maleate
AZD-2171,Recentin,西地尼布马来酸盐,AZD2171,AZD2171 maleate,AZD 2171 |
||
Cediranib is a potent and selective inhibitor of VEGF with antineoplastic activities. It inhibits all three vascular endothelial growth factor receptor (VEGF-1,-2,-3) tyrosine kinases, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth. |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-00949 |
VEGFR3/FLT4 Protein, Human, Recombinant (His)
VEGFR-3,PCL,FLT41,VEGF Receptor 3,VEGFR3,<... |
Human | HEK293 Cells |
VEGFR3/FLT4 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 86 kDa and the accession number is P35916-1. | |||
TMPY-01007 |
VEGFC Protein, Human, Recombinant (His)
血管内皮生长因子,LMPH1D,VEGF-C,Flt4-L,vascular end... |
Human | HEK293 Cells |
VEGFC Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 15.5 kDa and the accession number is P49767. | |||
TMPY-01936 |
VEGFR3/FLT4 Protein, Mouse, Recombinant (His)
Flt-4,VEGFR-3,Chy,fms related tyrosine kin... |
Mouse | HEK293 Cells |
VEGFR3/FLT4 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 86.4 kDa and the accession number is P35917-1. | |||
TMPK-00445 |
VEGFR3/FLT4 Protein, Human, Recombinant (His & Avi)
PCL,PCLFLT41,VEGFR3,FLT-4 |
Human | HEK293 Cells |
Vascular endothelial growth factor (VEGF) and its receptors VEGF-R1, -R2 and -R3 play important roles in tumor angiogenesis and are associated with poor prognosis in several solid tumors.VEGF-R1, -R2 and -R3 were highly expressed in CRC cells and stromal vessels. VEGF-R1 strong positive staining correlated with shorter survival after CRC surgery. VEGFR3/FLT4 Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 87.4 k... | |||
TMPY-01069 |
VEGFR3/FLT4 Protein, Human, Recombinant (hFc)
FLT41,fms related tyrosine kinase 4 |
Human | HEK293 Cells |
VEGFR3/FLT4 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 111.3 kDa and the accession number is P35916-1. | |||
TMPK-01043 |
VEGFC Protein, Human, Recombinant (His & Avi)
Flt4-L,血管内皮生长因子,VEGFC,VRP,VEGF-C |
Human | HEK293 Cells |
the lymphangiogenic factors vascular endothelial growth factor C (VEGFC) and VEGFD are cleaved by thrombin and plasmin, serine proteases generated during hemostasis and wound healing. Genetic studies reveal that platelet enhancement of lymphatic growth after wounding is dependent on the release of VEGFC, but not VEGFD, a finding consistent with high expression of VEGFC in both platelets and avian thrombocytes. VEGFC Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells w... | |||
TMPY-06620 |
VEGFR3/FLT4 Protein, Human, Recombinant (His & Avi), Biotinylated
PCL,VEGFR-3,LMPH1A,fms related tyrosine kinase 4, |
Human | HEK293 Cells |
VEGFR3/FLT4 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with His and Avi tag. The predicted molecular weight is 87.80 kDa and the accession number is NP_002011.2. | |||
TMPK-01044 |
VEGFC Protein, Human, Recombinant (His & Avi), Biotinylated
血管内皮生长因子,Flt4-L,VRP,VEGF-C,VEGFC |
Human | HEK293 Cells |
the lymphangiogenic factors vascular endothelial growth factor C (VEGFC) and VEGFD are cleaved by thrombin and plasmin, serine proteases generated during hemostasis and wound healing. Genetic studies reveal that platelet enhancement of lymphatic growth after wounding is dependent on the release of VEGFC, but not VEGFD, a finding consistent with high expression of VEGFC in both platelets and avian thrombocytes. VEGFC Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mam... | |||
TMPK-00446 |
VEGFR3/FLT4 Protein, Human, Recombinant (aa 25-776, His & Avi), Biotinylated
PCL,FLT-41,LMPH1A,FLT-4,... |
Human | HEK293 Cells |
Vascular endothelial growth factor (VEGF) and its receptors VEGF-R1, -R2 and -R3 play important roles in tumor angiogenesis and are associated with poor prognosis in several solid tumors.VEGF-R1, -R2 and -R3 were highly expressed in CRC cells and stromal vessels. VEGF-R1 strong positive staining correlated with shorter survival after CRC surgery. VEGFR3/FLT4 Protein, Human, Recombinant (aa 25-776, His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted m... | |||
TMPY-01937 |
VEGFR3/FLT4 Protein, Mouse, Recombinant (hFc)
VEGFR-3,fms related tyrosine kinase 4,VEGFR3,Fl... |
Mouse | HEK293 Cells |
VEGFR3/FLT4 Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 112 kDa and the accession number is P35917-1. |